Patent Oppositions in cancer drugs industry

Explore the competitive field of cancer drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in cancer drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the cancer drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the cancer drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Sep 24, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Stable, Concentrated Radionuclide Complex SolutionsADVANCED ACCELERATOR APPLICATIONSSep 9, 2026LUMARA BIO ONCOLOGICS
Stable, Concentrated Radionuclide Complex SolutionsADVANCED ACCELERATOR APPLICATIONSSep 9, 2026LUMARA BIO ONCOLOGICS
Stable, Concentrated Radionuclide Complex SolutionsADVANCED ACCELERATOR APPLICATIONSSep 9, 2026LUMARA BIO ONCOLOGICS
Lasofoxifene Modulation Of Membrane-Initiated Estrogen Signals And Methods For Tumor TreatmentWANGSep 3, 2026BRULIE
Method And Compositions For Inducing Differentiation Of Myeloid Derived Suppressor Cell To Treat Cancer And Infectious DiseasesOSE IMMUNOTHERAPEUTICSSep 3, 2026STRAWMAN
Binding Molecules For Bcma And Cd3AMGEN RESEARCH MUNICHAug 26, 2026REGENERON PHARMACEUTICALS
Combination Comprising An Mek Inhibitor And A B-Raf InhibitorNOVARTISAug 26, 2026HAMM&WITTKOPP PATENTANWÄLTE PARTMBB
Improved Method For Producing Antibody-Drug ConjugateDAIICHI SANKYOAug 25, 2026SANDOZ
Stable, Concentrated Radionuclide Complex SolutionsADVANCED ACCELERATOR APPLICATIONSAug 19, 2026WITHERS & ROGERS
Methods For Treating Cancer With Anti-Pd-1 AntibodiesMERCK SHARP & DOHMEAug 17, 2026WUESTHOFF & WUESTHOFF

To stay ahead in the competitive cancer drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the cancer drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Sep 24, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Apr 14, 2021Methods And Compositions For Treating CancerJANSSEN ONCOLOGY22
Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofAMGEN EUROPE15
Mar 10, 2021Novel Antitumoral Use Of CabazitaxelSANOFI13
Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA11
Jan 7, 2026Formulations Of EnzalutamideMEDIVATION PROSTATE THERAPEUTICS11
Oct 26, 2016Use Of Anti-Vegf Antibody In Combination With Chemotherapy For Treating Breast CancerF HOFFMANN LA ROCHE10
Aug 21, 2019Rapamycin Derivative For Treating Pancreas CancerNOVARTIS10
Feb 17, 2021Pharmaceutical Composition For Cancer TreatmentSHIONOGI10
Jan 13, 2021Method Of Treating Cancer Using Immune Checkpoint InhibitorBRISTOL MYERS SQUIBB9
May 20, 2015Treatment Of Solid Tumours With Rapamycin DerivativesNOVARTIS9